Company intelligence / Profile preview

Panoptes Pharma

Ownership: Private
Development stage: Phase 2

Overview

Panoptes developed PP-001, a third-generation nanomolar DHODH inhibitor formulated as intravitreal injection (PaniJect), eye drop (PaniDrop), and intravenous forms. Clinical milestones include demonstration of efficacy and safety in non-infectious posterior segment uveitis patients with PaniJect and a clinical safety study showing PaniDrop was well tolerated.

Therapeutic areas: OphthalmologyImmunologyNeurology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

PP-001

Phase 2

Indications: Ocular inflammation, Viral conjunctivitis

Partnerships

No major external partnerships disclosed prior to acquisition.

Beyond the preview

Go deeper on Panoptes Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Panoptes Pharma.

Explore the full profile